Where attention falls: Increased risk of falls from the converging impact of cortical cholinergic and midbrain dopamine loss on striatal function

Experimental Neurology

Volumn 257, Issue , 2014, Pages 120-129

  Sarter, Martin ^a   Albin, Roger L ^a,b   Kucinski, Aaron ^a   Lustig, Cindy ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Acetylcholine; Basal forebrain; Dopamine; Falls; Striatum

Indexed keywords

ACETYLCHOLINE; DOPAMINE; LEVODOPA; NICOTINIC AGENT; NICOTINIC RECEPTOR ALPHA4BETA2;

ACCIDENT PREVENTION; ACCIDENT PRONENESS; AGING; ATTENTION DISTURBANCE; BALANCE IMPAIRMENT; BODY POSTURE; BRAIN CORTEX; CELL INTERACTION; CELL LOSS; CHOLINERGIC NERVE CELL; CORPUS STRIATUM; DEAFFERENTATION; DISEASE ASSOCIATION; DOPAMINE BRAIN LEVEL; DOPAMINERGIC NERVE CELL; FALLING; FOREBRAIN; GAIT DISORDER; HUMAN; MESENCEPHALON; MOTOR DYSFUNCTION; NERVE PROJECTION; NEUROMODULATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SENSORIMOTOR INTEGRATION;

ACETYLCHOLINE; BASAL FOREBRAIN; DOPAMINE; FALLS; STRIATUM;

ACCIDENTAL FALLS; ACETYLCHOLINE; ANIMALS; ATTENTION; CEREBRAL CORTEX; CORPUS STRIATUM; DOPAMINE; HUMANS; MESENCEPHALON; PARKINSON DISEASE;

EID: 84900868270     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2014.04.032     Document Type: Review

References (193)

1. Aizenberg D., Sigler M., Weizman A., Barak Y. Anticholinergic burden and the risk of falls among elderly psychiatric inpatients: a 4-year case-control study. Int. Psychogeriatr. 2002, 14:307-310.
2. Allcock L.M., Rowan E.N., Steen I.N., Wesnes K., Kenny R.A., Burn D.J. Impaired attention predicts falling in Parkinson's disease. Parkinsonism Relat. Disord. 2009, 15:110-115.
3. Amboni M., Barone P., Hausdorff J.M. Cognitive contributions to gait and falls: evidence and implications. Mov. Disord. 2013, 28:1520-1533.
4. Apostol G., Abi-Saab W., Kratochvil C.J., Adler L.A., Robieson W.Z., Gault L.M., et al. Efficacy and safety of the novel α(4)β(2) neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study. Psychopharmacology (Berl.) 2011, 219:715-725.
5. Aracri P., Amadeo A., Pasini M.E., Fascio U., Becchetti A. Regulation of glutamate release by heteromeric nicotinic receptors in layer V of the secondary motor region (fr2) in the dorsomedial shoulder of prefrontal cortex in mouse. Synapse 2013, 67:338-357.
6. Arneric S.P., Campbell J.E., Carroll S., Daanen J.F., Holladay M.W., Johnson P., et al. ABT-089 [3-(2 (S)-pyrrolidinylmethoxy)-2-methyl-pyridine]: an orally effective cholinergic channel modulator with potential once-a-day dosing and cardiovascular safety. Drug Dev. Res. 1997, 41:31-43.
7. Ayers E.I., Tow A.C., Holtzer R., Verghese J. Walking while talking and falls in aging. Gerontology 2013, 60:108-113.
8. Bain E.E., Robieson W., Pritchett Y., Garimella T., Abi-Saab W., Apostol G., et al. A randomized, double-blind, placebo-controlled phase 2 study of α4β2 agonist ABT-894 in adults with ADHD. Neuropsychopharmacology 2013, 38:405-413.
9. Baker S.P., Harvey A.H. Fall injuries in the elderly. Clin. Geriatr. Med. 1985, 1:501-512.
10. Balash Y., Peretz C., Leibovich G., Herman T., Hausdorff J.M., Giladi N. Falls in outpatients with Parkinson's disease: frequency, impact and identifying factors. J. Neurol. 2005, 252:1310-1315.
11. Bamford N.S., Robinson S., Palmiter R.D., Joyce J.A., Moore C., Meshul C.K. Dopamine modulates release from corticostriatal terminals. J. Neurosci. 2004, 24:9541-9552.
12. Bartus R.T., Dean R.L., Beer B., Lippa A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982, 217:408-414.
13. Baunez C., Robbins T.W. Effects of dopamine depletion of the dorsal striatum and further interaction with subthalamic nucleus lesions in an attentional task in the rat. Neuroscience 1999, 92:1343-1356.
14. Berdot S., Bertrand M., Dartigues J.F., Fourrier A., Tavernier B., Ritchie K., et al. Inappropriate medication use and risk of falls-a prospective study in a large community-dwelling elderly cohort. BMC Geriatr. 2009, 9:30.
15. Bhutani N., Sureshbabu R., Farooqui A., Behari M., Goyal V., Murthy A. Queuing of concurrent movement plans by basal ganglia. J. Neurosci. 2013, 33:9985-9997.
16. Bohnen N.I., Albin R.L. Cholinergic denervation occurs early in Parkinson disease. Neurology 2009, 73:256-257.
17. Bohnen N.I., Albin R.L. The cholinergic system and Parkinson disease. Behav. Brain Res. 2011, 221:564-573.
18. Bohnen N.I., Frey K.A. Imaging of cholinergic and monoaminergic neurochemical changes in neurodegenerative disorders. Mol. Imaging Biol. 2007, 9:243-257.
19. Bohnen N.I., Kaufer D.I., Ivanco L.S., Lopresti B., Koeppe R.A., Davis J.G., et al. Cortical cholinergic function is more severely affected in Parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch. Neurol. 2003, 60:1745-1748.
20. Bohnen N.I., Muller M.L., Kuwabara H., Cham R., Constantine G.M., Studenski S.A. Age-associated striatal dopaminergic denervation and falls in community-dwelling subjects. J. Rehabil. Res. Dev. 2009, 46:1045-1052.
21. Bohnen N.I., Müller M.L., Koeppe R.A., Studenski S.A., Kilbourn M.A., Frey K.A., et al. History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology 2009, 73:1670-1676.
22. Bohnen N.I., Müller M.L.T.M., Kotagal V., Koeppe R.A., Kilbourn M.R., Gilman S., et al. Heterogeneity of cholinergic denervation in Parkinson's disease without dementia. J. Cereb. Blood Flow Metab. 2012, 32:1609-1617.
23. Bohnen N.I., Frey K.A., Studenski S., Kotagal V., Koeppe R.A., Scott P.J., et al. Gait speed in Parkinson disease correlates with cholinergic degeneration. Neurology 2013, 81:1611-1616.
24. Botly L.C., De Rosa E. Cholinergic deafferentation of the neocortex using 192 IgG-saporin impairs feature binding in rats. J. Neurosci. 2009, 29:4120-4130.
25. Bradfield L., Bertran-Gonzalez J., Chieng B., Balleine B. The thalamostriatal pathway and cholinergic control of goal-directed action: interlacing new with existing learning in the striatum. Neuron 2013, 79:153-166.
26. Bridenbaugh S.A., Kressig R.W. Laboratory review: the role of gait analysis in seniors' mobility and fall prevention. Gerontology 2011, 57:256-264.
27. Brown L.A., Shumway-Cook A., Woollacott M.H. Attentional demands and postural recovery: the effects of aging. J. Gerontol. A Biol. Sci. Med. Sci. 1999, 54:M165-M171.
28. Bucci D.J., Holland P.C., Gallagher M. Removal of cholinergic input to rat posterior parietal cortex disrupts incremental processing of conditioned stimuli. J. Neurosci. 1998, 18:8038-8046.
29. Burk J.A., Herzog C.D., Porter M.C., Sarter M. Interactions between aging and cortical cholinergic deafferentation on attention. Neurobiol. Aging 2002, 23:467-477.
30. Candy J.M., Perry R.H., Perry E.K., Irving D., Blessed G., Fairbairn A.F., et al. Pathological changes in the nucleus of Meynert in Alzheimer's and Parkinson's diseases. J. Neurol. Sci. 1983, 59:277-289.
31. Cham R., Studenski S.A., Perera S., Bohnen N.I. Striatal dopaminergic denervation and gait in healthy adults. Exp. Brain Res. 2008, 185:391-398.
32. Cham R., Perera S., Studenski S.A., Bohnen N.I. Age-related striatal dopaminergic denervation and severity of a slip perturbation. J. Gerontol. A Biol. Sci. Med. Sci. 2011, 66:980-985.
33. Chen H.C., Schultz A.B., Ashton-Miller J.A., Giordani B., Alexander N.B., Guire K.E. Stepping over obstacles: dividing attention impairs performance of old more than young adults. J. Gerontol. A Biol. Sci. Med. Sci. 1996, 51:M116-M122.
34. Chung K.A., Lobb B.M., Nutt J.G., Horak F.B. Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease. Neurology 2010, 75:1263-1269.
35. Coelho F.G., Stella F., de Andrade L.P., Barbieri F.A., Santos-Galduróz R.F., Gobbi S., et al. Gait and risk of falls associated with frontal cognitive functions at different stages of Alzheimer's disease. Neuropsychol. Dev. Cogn. B Aging Neuropsychol. Cogn. 2012, 19:644-656.
36. Cole M.H., Silburn P.A., Wood J.M., Worringham C.J., Kerr G.K. Falls in Parkinson's disease: kinematic evidence for impaired head and trunk control. Mov. Disord. 2010, 25:2369-2378.
37. Cole M.H., Silburn P.A., Wood J.M., Kerr G.K. Falls in Parkinson's disease: evidence for altered stepping strategies on compliant surfaces. Parkinsonism Relat. Disord. 2011, 17:610-616.
38. Cools R., Barker R.A., Sahakian B.J., Robbins T.W. Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. Cereb. Cortex 2001, 11:1136-1143.
39. Cowie D., Limousin P., Peters A., Hariz M., Day B.L. Doorway-provoked freezing of gait in Parkinson's disease. Mov. Disord. 2012, 27:492-499.
40. Craik F.I., Luo L., Sakuta Y. Effects of aging and divided attention on memory for items and their contexts. Psychol. Aging 2010, 25:968-979.
41. Crofts H.S., Dalley J.W., Collins P., Van Denderen J.C., Everitt B.J., Robbins T.W., et al. Differential effects of 6-OHDA lesions of the frontal cortex and caudate nucleus on the ability to acquire an attentional set. Cereb. Cortex 2001, 11:1015-1026.
42. Crossley M., Hiscock M. Age-related differences in concurrent-task performance of normal adults: evidence for a decline in processing resources. Psychol. Aging 1992, 7:499-506.
43. Dalley J.W., Theobald D.E., Bouger P., Chudasama Y., Cardinal R.N., Robbins T.W. Cortical cholinergic function and deficits in visual attentional performance in rats following 192 IgG-saporin-induced lesions of the medial prefrontal cortex. Cereb. Cortex 2004, 14:922-932.
44. Darbin O. The aging striatal dopamine function. Parkinsonism Relat. Disord. 2012, 18:426-432.
45. Darvas M., Palmiter R.D. Restriction of dopamine signaling to the dorsolateral striatum is sufficient for many cognitive behaviors. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:14664-14669.
46. Decamp E., Schneider J.S. Interaction between nicotinic and dopaminergic therapies on cognition in a chronic Parkinson model. Brain Res. 2009, 1262:109-114.
47. Deco G., Thiele A. Attention: oscillations and neuropharmacology. Eur. J. Neurosci. 2009, 30:347-354.
48. Dellinger A.M., Stevens J.A. The injury problem among older adults: mortality, morbidity and costs. J. Saf. Res. 2006, 37:519-522.
49. Demeter E., Sarter M., Lustig C. Rats and humans paying attention: cross-species task development for translational research. Neuropsychology 2008, 22:787-799.
50. Deumens R., Blokland A., Prickaerts J. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp. Neurol. 2002, 175:303-317.
51. Devan B.D., McDonald R.J., White N.M. Effects of medial and lateral caudate-putamen lesions on place- and cue-guided behaviors in the water maze: relation to thigmotaxis. Behav. Brain Res. 1999, 100:5-14.
52. Dickinson J.A., Kew J.N., Wonnacott S. Presynaptic alpha 7- and beta 2-containing nicotinic acetylcholine receptors modulate excitatory amino acid release from rat prefrontal cortex nerve terminals via distinct cellular mechanisms. Mol. Pharmacol. 2008, 74:348-359.
53. Disney A.A., Aoki C. Muscarinic acetylcholine receptors in macaque V1 are most frequently expressed by parvalbumin-immunoreactive neurons. J. Comp. Neurol. 2008, 507:1748-1762.
54. Disney A., Aoki C., Hawken J. Cholinergic suppression of visual responses in primate V1 is mediated by GABAergic inhibition. J. Neurophysiol. 2012, 108:1907-1923.
55. Domenger D., Schwarting R.K. Effects of neostriatal 6-OHDA lesion on performance in a rat sequential reaction time task. Neurosci. Lett. 2008, 444:212-216.
56. Dubé L., Smith A.D., Bolam J.P. Identification of synaptic terminals of thalamic or cortical origin in contact with distinct medium-size spiny neurons in the rat neostriatum. J. Comp. Neurol. 1988, 267:455-471.
57. Düzel S., Münte T.F., Lindenberger U., Bunzeck N., Schütze H., Heinze H.J., et al. Basal forebrain integrity and cognitive memory profile in healthy aging. Brain Res. 2010, 1308:124-136.
58. Eggermann E., Feldmeyer D. Cholinergic filtering in the recurrent excitatory microcircuit of cortical layer 4. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:11753-11758.
59. Egorov A.V., Hamam B.N., Fransén E., Hasselmo M.E., Alonso A.A. Graded persistent activity in entorhinal cortex neurons. Nature 2002, 420:173-178.
60. Fasano A., Plotnik M., Bove F., Berardelli A. The neurobiology of falls. Neurol. Sci. 2012, 33:1215-1223.
61. Fernández P.J., Campoy G., García Santos J.M., Antequera M.M., García-Sevilla J., Castillo A., et al. Is there a specific pattern of attention deficit in mild cognitive impairment with subcortical vascular features? Evidence from the attention network test. Dement. Geriatr. Cogn. Disord. 2011, 31:268-275.
62. Freeze S., Kravitz V., Hammack N., Berke D., Kreitzer C. Control of basal ganglia output by direct and indirect pathway projection neurons. J. Neurosci. 2013, 33:18531-18539.
63. Fries P. A mechanism for cognitive dynamics: neuronal communication through neuronal coherence. Trends Cogn. Sci. 2005, 9:474-480.
64. Gauntlett-Gilbert J., Roberts R.C., Brown V.J. Mechanisms underlying attentional set-shifting in Parkinson's disease. Neuropsychologia 1999, 37:605-616.
65. Gepshtein S., Li X., Snider J., Plank M., Lee D., Poizner H. Dopamine function and the efficiency of human movement. J. Cogn. Neurosci. 2014, 26:645-657.
66. Geula C., Mesulam M.M. Cortical cholinergic fibers in aging and Alzheimer's disease: a morphometric study. Neuroscience 1989, 33:469-481.
67. Geula C., Nagykery N., Nicholas A., Wu C.K. Cholinergic neuronal and axonal abnormalities are present early in aging and in Alzheimer disease. J. Neuropathol. Exp. Neurol. 2008, 67:309-318.
68. Granacher U., Bridenbaugh S.A., Muehlbauer T., Wehrle A., Kressig R.W. Age-related effects on postural control under multi-task conditions. Gerontology 2011, 57:247-255.
69. Grimbergen Y.A., Munneke M., Bloem B.R. Falls in Parkinson's disease. Curr. Opin. Neurol. 2004, 17:405-415.
70. Gritti I., Henny P., Galloni F., Mainville L., Mariotti M., Jones B.E. Stereological estimates of the basal forebrain cell population in the rat, including neurons containing choline acetyltransferase, glutamic acid decarboxylase or phosphate-activated glutaminase and colocalizing vesicular glutamate transporters. Neuroscience 2006, 143:1051-1064.
71. Gritton H., Mallory C.S., Hetrick V.L., Berke J.D., Sarter M. Bidirectional optogenetic control of cortical acetylcholine signaling demonstrates vital contributions to attentional performance. Society for Neuroscience Abstracts 2012, (abstract # 913.16).
72. Grothe M., Heinsen H., Teipel S.J. Atrophy of the cholinergic basal forebrain over the adult age range and in early stages of Alzheimer's disease. Biol. Psychiatry 2012, 71:805-813.
73. Grothe M., Heinsen H., Teipel S. Longitudinal measures of cholinergic forebrain atrophy in the transition from healthy aging to Alzheimer's disease. Neurobiol. Aging 2013, 34:1210-1220.
74. Guillem K., Bloem B., Poorthuis R.B., Loos M., Smit A.B., Maskos U., et al. Nicotinic acetylcholine receptor β2 subunits in the medial prefrontal cortex control attention. Science 2011, 333:888-891.
75. Gulledge A.T., Stuart G.J. Cholinergic inhibition of neocortical pyramidal neurons. J. Neurosci. 2005, 25:10308-10320.
76. Guthrie M., Leblois A., Garenne A., Boraud T. Interaction between cognitive and motor cortico-basal ganglia loops during decision making: a computational study. J. Neurophysiol. 2013, 109:3025-3040.
77. Haber S.N. The primate basal ganglia: parallel and integrative networks. J. Chem. Neuroanat. 2003, 26:317-330.
78. Hall D., Echt V., Wolf L., Rogers A. Cognitive and motor mechanisms underlying older adults' ability to divide attention while walking. Phys. Ther. 2011, 91:1039-1050.
79. Hasselmo M.E., Bower J.M. Cholinergic suppression specific to intrinsic not afferent fiber synapses in rat piriform (olfactory) cortex. J. Neurophysiol. 1992, 67:1222-1229.
80. Hasselmo M.E., Sarter M. Modes and models of forebrain cholinergic neuromodulation of cognition. Neuropsychopharmacology 2011, 36:52-73.
81. Hauber W., Schmidt W.J. Differential effects of lesions of the dorsomedial and dorsolateral caudate-putamen on reaction time performance in rats. Behav. Brain Res. 1994, 60:211-215.
82. Hausdorff J.M., Doniger G.M., Springer S., Yogev G., Simon E.S., Giladi N. A common cognitive profile in elderly fallers and in patients with Parkinson's disease: the prominence of impaired executive function and attention. Exp. Aging Res. 2006, 32:411-429.
83. Herrero J.L., Roberts M.J., Delicato L.S., Gieselmann M.A., Dayan P., Thiele A. Acetylcholine contributes through muscarinic receptors to attentional modulation in V1. Nature 2008, 454:1110-1114.
84. Hirsch E.C., Graybiel A.M., Duyckaerts C., Javoy-Agid F. Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy. PNAS U. S. A. 1987, 84:5976.
85. Holtzer R., Friedman R., Lipton R.B., Katz M., Xue X., Verghese J. The relationship between specific cognitive functions and falls in aging. Neuropsychology 2007, 21:540-548.
86. Howe W.M., Ji J., Parikh V., Williams S., Mocaër E., Trocmé-Thibierge C., et al. Enhancement of attentional performance by selective stimulation of alpha4beta2* nAChRs: underlying cholinergic mechanisms. Neuropsychopharmacology 2010, 35:1391-1401.
87. Howe W.M., Gritton H., Berke J., Sarter M. Attention-demanding cues evoke prefrontal gamma oscillations and are differentially modulated by prefrontal muscarinic and nicotinic receptors. Society for Neuroscience Abstracts 2011, (abstract # 197.09).
88. Howe W.M., Berry A.S., Francois J., Gilmour G., Carp J.M., Tricklebank M., et al. Prefrontal cholinergic mechanisms instigating shifts from monitoring for cues to cue-guided performance: converging electrochemical and fMRI evidence from rats and humans. J. Neurosci. 2013, 33:8742-8752.
89. Hsu C.L., Nagamatsu L.S., Davis J.C., Liu-Ambrose T. Examining the relationship between specific cognitive processes and falls risk in older adults: a systematic review. Osteoporos. Int. 2012, 23:2409-2424.
90. Huang L.Z., Campos C., Ly J., Ivy Carroll F., Quik M. Nicotinic receptor agonists decrease l-dopa-induced dyskinesias most effectively in partially lesioned Parkinsonian rats. Neuropharmacology 2011, 60:861-868.
91. Hurley P.J., Elsworth J.D., Whittaker M.C., Roth R.H., Redmond D.E. Aged monkeys as a partial model for Parkinson's disease. Pharmacol. Biochem. Behav. 2011, 99:324-332.
92. Ikonomovic M.D., Mufson E.J., Wuu J., Bennett D.A., DeKosky S.T. Reduction of choline acetyltransferase activity in primary visual cortex in mild to moderate Alzheimer's disease. Arch. Neurol. 2005, 62:425-430.
93. Kang H.G., Costa M.D., Priplata A.A., Starobinets O.V., Goldberger A.L., Peng C.K., et al. Frailty and the degradation of complex balance dynamics during a dual-task protocol. J. Gerontol. A Biol. Sci. Med. Sci. 2009, 64:1304-1311.
94. Karachi C., Grabli D., Bernard F.A., Tandé D., Wattiez N., Belaid H., et al. Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease. J. Clin. Investig. 2010, 120:2745-2754.
95. Kim H., Lee D., Jung W. Signals for previous goal choice persist in the dorsomedial, but not dorsolateral striatum of rats. J. Neurosci. 2013, 33:52-63.
96. Koop M.M., Hill B.C., Bronte-Stewart H.M. Perceptual errors increase with movement duration and may contribute to hypokinesia in Parkinson's disease. Neuroscience 2013, 243:1-13.
97. Kucinski A., Paolone G., Petersen C.C., Ronan E.A., Albin R.L., Sarter M. Deficits in the attentional control of posture and complex movements in a rat model of early state, multisystem Parkinson's disease. Society for Neuroscience Abstracts 2012, (abstract # 5112).
98. Kucinski A., Paolone G., Bradshaw M., Albin R.L., Sarter M. Modeling fall propensity in Parkinson's disease: deficits in the attentional control of complex movements in rats with cortical-cholinergic and striatal-dopaminergic deafferentation. J. Neurosci. 2013, 33:16522-16539.
99. Kurz I., Berezowski E., Melzer I. Frontal plane instability following rapid voluntary stepping: effects of age and a concurrent cognitive task. J. Gerontol. A Biol. Sci. Med. Sci. 2013, 68:1402-1408.
100. Kurzban R., Duckworth A., Kable J.W., Myers J. An opportunity cost model of subjective effort and task performance. Behav. Brain Sci. 2013, 36:661-679.
101. Lambe E.K., Picciotto M.R., Aghajanian G.K. Nicotine induces glutamate release from thalamocortical terminals in prefrontal cortex. Neuropsychopharmacology 2003, 28:216-225.
102. LaPointe L.L., Stierwalt J.A.G., Maitland C.G. Talking while walking: cognitive loading and injurious falls in Parkinson's disease. Int. J. Speech Lang. Pathol. 2010, 12:455-459.
103. Lex B., Hauber W. The role of dopamine in the prelimbic cortex and the dorsomedial striatum in instrumental conditioning. Cereb. Cortex 2010, 20:873-883.
104. Li K.Z., Lindenberger U., Freund A.M., Baltes P.B. Walking while memorizing: age-related differences in compensatory behavior. Psychol. Sci. 2001, 12:230-237.
105. Lin S.C., Gervasoni D., Nicolelis M.A. Fast modulation of prefrontal cortex activity by basal forebrain noncholinergic neuronal ensembles. J. Neurophysiol. 2006, 96:3209-3219.
106. Lord S., Rochester L., Hetherington V., Allcock L.M., Burn D. Executive dysfunction and attention contribute to gait interference in 'off' state Parkinson's disease. Gait Posture 2010, 31:169-174.
107. Luiten P.G., Gaykema R.P., Traber J., Spencer D.G. Cortical projection patterns of magnocellular basal nucleus subdivisions as revealed by anterogradely transported Phaseolus vulgaris leucoagglutinin. Brain Res. 1987, 413:229-250.
108. Mailly P., Aliane V., Groenewegen H.J., Haber S.N., Deniau J.M. The rat prefrontostriatal system analyzed in 3D: evidence for multiple interacting functional units. J. Neurosci. 2013, 33:5718-5727.
109. Marchese R., Bove M., Abbruzzese G. Effect of cognitive and motor tasks on postural stability in Parkinson's disease: a posturographic study. Mov. Disord. 2003, 18:652-658.
110. Matell M.S., Meck W.H., Lustig C. Not "just" a coincidence: frontal-striatal interactions in working memory and interval timing. Memory 2007, 13:441-448.
111. Mattila P.M., Röyttä M., Lönnberg P., Marjamäki P., Helenius H., Rinne J.O. Choline acetyltransferase activity and striatal dopamine receptors in Parkinson's disease in relation to cognitive impairment. Acta Neuropathol. 2001, 102:160-166.
112. Mazzoni P., Hristova A., Krakauer J.W. Why don't we move faster? Parkinson's disease, movement vigor, and implicit motivation. J. Neurosci. 2007, 27:7105-7116.
113. McGaughy J., Sarter M. Sustained attention performance in rats with intracortical infusions of 192 IgG-saporin-induced cortical cholinergic deafferentation: effects of physostigmine and FG 7142. Behav. Neurosci. 1998, 112:1519-1525.
114. McGaughy J., Kaiser T., Sarter M. Behavioral vigilance following infusions of 192 IgG-saporin into the basal forebrain: selectivity of the behavioral impairment and relation to cortical ache-positive fiber density. Behav. Neurosci. 1996, 110:247-265.
115. McGaughy J., Everitt B.J., Robbins T.W., Sarter M. The role of cortical cholinergic afferent projections in cognition: impact of new selective immunotoxins. Behav. Brain Res. 2000, 115:251-263.
116. McNeely M.E., Duncan R.P., Earhart G.M. Medication improves balance and complex gait performance in Parkinson disease. Gait Posture 2013, 19:86-91.
117. Mersmann F., Bohm S., Bierbaum S., Dietrich R., Arampatzis A. Young and old adults prioritize dynamic stability control following gait perturbations when performing a concurrent cognitive task. Gait Posture 2013, 37:373-377.
118. Montero-Odasso M., Muir S.W., Speechley M. Dual-task complexity affects gait in people with mild cognitive impairment: the interplay between gait variability, dual tasking, and risk of falls. Arch. Phys. Med. Rehabil. 2012, 93:293-299.
119. Montero-Odasso M., Verghese J., Beauchet O., Hausdorff J.M. Gait and cognition: a complementary approach to understanding brain function and the risk of falling. J. Am. Geriatr. Soc. 2012, 60:2127-2136.
120. Muller M.L.T.M., Albin R.L., Kotagal V., Koeppe R.A., Scott P.J.H., Frey K.A., et al. Thalamic cholinergic innervation and postural sensory integration function in Parkinson's disease. Brain 2013, 136:3282-3289.
121. Nagamatsu L.S., Munkacsy M., Liu-Ambrose T., Handy T.C. Altered visual-spatial attention to task-irrelevant information is associated with falls risk in older adults. Neuropsychologia 2013, 51:3025-3032.
122. Naismith S.L., Shine J.M., Lewis S.J. The specific contributions of set-shifting to freezing of gait in Parkinson's disease. Mov. Disord. 2010, 25:1000-1004.
123. Nakano I., Hirano A. Parkinson's disease: neuron loss in the nucleus basalis without concomitant Alzheimer's disease. Ann. Neurol. 1984, 15:415-418.
124. Navon D. Resources: a theoretical soup stone?. Psychol. Rev. 1984, 91:216.
125. Nelson C.L., Sarter M., Bruno J.P. Prefrontal cortical modulation of acetylcholine release in posterior parietal cortex. Neuroscience 2005, 132:347-359.
126. Newman L.A., McGaughy J. Cholinergic deafferentation of prefrontal cortex increases sensitivity to cross-modal distractors during a sustained attention task. J. Neurosci. 2008, 28:2642-2650.
127. Newman E.L., Gillet S.N., Climer J.R., Hasselmo M.E. Cholinergic blockade reduces theta-gamma phase amplitude coupling and speed modulation of theta frequency consistent with behavioral effects on encoding. J. Neurosci. 2013, 33:19635-19646.
128. Niv Y., Daw N.D., Joel D., Dayan P. Tonic dopamine: opportunity costs and the control of response vigor. Psychopharmacology (Berl.) 2007, 191:507-520.
129. O'Halloran A.M., Pénard N., Galli A., Fan C., Robertson I.H., Kenny R. Falls and falls efficacy: the role of sustained attention in older adults. BMC Geriatr. 2011, 11:1-10.
130. Ossandón T., Jerbi K., Vidal J.R., Bayle D.J., Henaff M.A., Jung J., et al. Transient suppression of broadband gamma power in the default-mode network is correlated with task complexity and subject performance. J. Neurosci. 2011, 31:14521-14530.
131. Pahapill P.A., Lozano A.M. The pedunculopontine nucleus and Parkinson's disease. Brain 2000, 123:1767-1783.
132. Paolone G., Angelakos C.C., Meyer P.J., Robinson T.E., Sarter M. Cholinergic control over attention in rats prone to attribute incentive salience to reward cues. J. Neurosci. 2013, 33:8321-8335.
133. Parikh V., Kozak R., Martinez V., Sarter M. Prefrontal acetylcholine release controls cue detection on multiple time scales. Neuron 2007, 56:141-154.
134. Parikh V., Sarter M. Cholinergic mediation of attention: contributions of phasic and tonic increases in prefrontal cholinergic activity. Ann. N. Y. Acad. Sci. 2008, 1129:225-235.
135. Parikh V., Man K., Decker M.W., Sarter M. Glutamatergic contributions to nicotinic acetylcholine receptor agonist-evoked cholinergic transients in the prefrontal cortex. J. Neurosci. 2008, 28:3769-3780.
136. Parikh V., Ji J., Decker M.W., Sarter M. Prefrontal beta2 subunit-containing and alpha7 nicotinic acetylcholine receptors differentially control glutamatergic and cholinergic signaling. J. Neurosci. 2010, 30:3518-3530.
137. Parikh V., Howe W.M., Welchko R.M., Naughton S.X., D'Amore D.E., Han D.H., et al. Diminished trka receptor signaling reveals cholinergic-attentional vulnerability of aging. Eur. J. Neurosci. 2012, 37:278-293.
138. Parkinson Study Group Randomized placebo-controlled study of the nicotinic agonist SIB-1508Y in Parkinson disease. Neurology 2006, 66:408-410.
139. Paul S.S., Sherrington C., Canning C.G., Fung V.S., Close J.C., Lord S.R. The relative contribution of physical and cognitive fall risk factors in people with Parkinson's disease: a large prospective cohort study. Neurorehabil. Neural Repair 2013, 28:282-290.
140. Persad C.C., Jones J.L., Ashton-Miller J.A., Alexander N.B., Giordani B. Executive function and gait in older adults with cognitive impairment. J. Gerontol. A Biol. Sci. Med. Sci. 2008, 63:1350-1355.
141. Pickel V.M., Beckley S.C., Joh T.H., Reis D.J. Ultrastructural immunocytochemical localization of tyrosine hydroxylase in the neostriatum. Brain Res. 1981, 225:373-385.
142. Plotnik M., Giladi N., Dagan Y., Hausdorff J.M. Postural instability and fall risk in Parkinson's disease: impaired dual tasking, pacing, and bilateral coordination of gait during the "ON" medication state. Exp. Brain Res. 2011, 210:529-538.
143. Posner M.I., Snyder C.R., Davidson B.J. Attention and the detection of signals. J. Exp. Psychol. 1980, 109:160-174.
144. Possin K.L., Kang G.A., Guo C., Fine E.M., Trujillo A.J., Racine C.A., et al. Rivastigmine is associated with restoration of left frontal brain activity in Parkinson's disease. Mov. Disord. 2013, 28:1384-1390.
145. Quik M., O'Leary K., Tanner C.M. Nicotine and Parkinson's disease: implications for therapy. Mov. Disord. 2008, 23:1641-1652.
146. Reep R.L., Cheatwood J.L., Corwin J.V. The associative striatum: organization of cortical projections to the dorsocentral striatum in rats. J. Comp. Neurol. 2003, 467:271-292.
147. Rogers R.D., Baunez C., Everitt B.J., Robbins T.W. Lesions of the medial and lateral striatum in the rat produce differential deficits in attentional performance. Behav. Neurosci. 2001, 115:799-811.
148. Salthouse T.A., Fristoe N.M., Lineweaver T.T., Coon V.E. Aging of attention: does the ability to divide decline?. Mem. Cogn. 1995, 23:59-71.
149. Sarter M., Bruno J.P. Age-related changes in rodent cortical acetylcholine and cognition: main effects of age versus age as an intervening variable. Brain Res. Rev. 1998, 27:143-156.
150. Sarter M., Turchi J. Age- and dementia-associated impairments in divided attention: psychological constructs, animal models, and underlying neuronal mechanisms. Dement. Geriatr. Cogn. Disord. 2002, 13:46-58.
151. Sarter M., Givens B., Bruno J.P. The cognitive neuroscience of sustained attention: where top-down meets bottom-up. Brain Res. Rev. 2001, 35:146-160.
152. Sarter M., Bruno J.P., Givens B. Attentional functions of cortical cholinergic inputs: what does it mean for learning and memory?. Neurobiol. Learn. Mem. 2003, 80:245-256.
153. Sarter M., Gehring W.J., Kozak R. More attention must be paid: the neurobiology of attentional effort. Brain Res. Rev. 2006, 51:145-160.
154. Sarter M., Parikh V., Howe W.M. NAChR agonist-induced cognition enhancement: integration of cognitive and neuronal mechanisms. Biochem. Pharmacol. 2009, 78:658-667.
155. Sarter M., Lustig C., Howe W.M., Gritton H., Berry A.S. Deterministic functions of cortical acetylcholine. Eur. J. NeuroSci. 2014, (in press).
156. Schliebs R., Arendt T. The cholinergic system in aging and neuronal degeneration. Behav. Brain Res. 2011, 221:555-563.
157. Schneider J.S., Van Velson M., Menzaghi F., Lloyd G.K. Effects of the nicotinic acetylcholine receptor agonist SIB-1508Y on object retrieval performance in mptp-treated monkeys: comparison with levodopa treatment. Ann. Neurol. 1998, 43:311-317.
158. Schneider J.S., Tinker J.P., Van Velson M., Menzaghi F., Lloyd G.K. Nicotinic acetylcholine receptor agonist SIB-1508Y improves cognitive functioning in chronic low-dose MPTP-treated monkeys. J. Pharmacol. Exp. Ther. 1999, 290:731-739.
159. Schneider J.S., Tinker J.P., Menzaghi F., Lloyd G.K. The subtype-selective nicotinic acetylcholine receptor agonist SIB-1553A improves both attention and memory components of a spatial working memory task in chronic low dose 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys. J. Pharmacol. Exp. Ther. 2003, 306:401-406.
160. Sethi K. Levodopa unresponsive symptoms in Parkinson disease. Mov. Disord. 2008, 23:S521-S533.
161. Shimada H., Hirano S., Shinotoh H., Aotsuka A., Sato K., Tanaka N., et al. Mapping of brain acetylcholinesterase alterations in lewy body disease by PET. Neurology 2009, 73:273-278.
162. Shumway-Cook A., Woollacott M. Attentional demands and postural control: the effect of sensory context. J. Gerontol. A Biol. Sci. Med. Sci. 2000, 55:M10-M16.
163. Springer S., Giladi N., Peretz C., Yogev G., Simon E.S., Hausdorff J.M. Dual-tasking effects on gait variability: the role of aging, falls, and executive function. Mov. Disord. 2006, 21:950-957.
164. St Peters M., Demeter E., Lustig C., Bruno J.P., Sarter M. Enhanced control of attention by stimulating mesolimbic-corticopetal cholinergic circuitry. J. Neurosci. 2011, 31:9760-9771.
165. Strafella A.P., Ko J.H., Grant J., Fraraccio M., Monchi O. Corticostriatal functional interactions in Parkinson's disease: A rtms/[11C]raclopride PET study. Eur. J. Neurosci. 2005, 22:2946-2952.
166. Theill N., Martin M., Schumacher V., Bridenbaugh S.A., Kressig R.W. Simultaneously measuring gait and cognitive performance in cognitively healthy and cognitively impaired older adults: the Basel motor-cognition dual-task paradigm. J. Am. Geriatr. Soc. 2011, 59:1012-1018.
167. Thiele A., Herrero J.L., Distler C., Hoffmann K.P. Contribution of cholinergic and gabaergic mechanisms to direction tuning, discriminability, response reliability, and neuronal rate correlations in macaque middle temporal area. J. Neurosci. 2012, 32:16602-16615.
168. Tinetti M.E., Speechley M., Ginter S.F. Risk factors for falls among elderly persons living in the community. N. Engl. J. Med. 1988, 319:1701-1707.
169. Tombu M., Jolicœur P. A central capacity sharing model of dual-task performance. J. Exp. Psychol. Hum. Percept. Perform. 2003, 29:3-18.
170. Troiano A.R., Schulzer M., de la Fuente-Fernandez R., Mak E., McKenzie J., Sossi V., et al. Dopamine transporter PET in normal aging: dopamine transporter decline and its possible role in preservation of motor function. Synapse 2010, 64:146-151.
171. Turchi J., Sarter M. Cortical acetylcholine and processing capacity: effects of cortical cholinergic deafferentation on crossmodal divided attention in rats. Cogn. Brain Res. 1997, 6:147-158.
172. Uemura K., Yamada M., Nagai K., Ichihashi N. Older adults at high risk of falling need more time for anticipatory postural adjustment in the precrossing phase of obstacle negotiation. J. Gerontol. A Biol. Sci. Med. Sci. 2011, 66:904-909.
173. Uemura K., Yamada M., Nagai K., Tanaka B., Mori S. Impaired choice stepping in response to a visual-spatial attention demanding task among older adults at high risk of falling: a pilot study. Aging Clin. Exp. Res. 2012, 24:361-364.
174. van Schouwenburg R., O'Shea J., Mars B., Rushworth M.F.S., Cools R. Controlling human striatal cognitive function via the frontal cortex. J. Neurosci. 2012, 32:5631-5637.
175. Wall N., De La Parra M., Callaway E., Kreitzer A. Differential innervation of direct- and indirect-pathway striatal projection neurons. Neuron 2013, 79:347-360.
176. Wang A.Y., Miura K., Uchida N. The dorsomedial striatum encodes net expected return, critical for energizing performance vigor. Nat. Neurosci. 2013, 16:639-647.
177. Whitehouse P.J., Hedreen J.C., White C.L., Price D.L. Basal forebrain neurons in the dementia of Parkinson disease. Ann. Neurol. 1983, 13:243-248.
178. Wilson N.M., Hilmer S.N., March L.M., Cameron I.D., Lord S.R., Seibel M.J., et al. Associations between drug burden index and falls in older people in residential aged care. J. Am. Geriatr. Soc. 2011, 59:875-880.
179. Wolf D., Grothe M., Fischer F.U., Heinsen H., Kilimann I., Teipel S., et al. Association of basal forebrain volumes and cognition in normal aging. Neuropsychologia 2013, 53C:54-63.
180. Wood B.H. Incidence and prediction of falls in Parkinson's disease: a prospective multidisciplinary study. J. Neurol. Neurosurg. Psychiatry 2002, 72:721-725.
181. Woollacott M., Shumway-Cook A. Attention and the control of posture and gait: a review of an emerging area of research. Gait Posture 2002, 16:1-14.
182. Wu T., Hallett M. A functional MRI study of automatic movements in patients with Parkinson's disease. Brain 2005, 128:2250-2259.
183. Yarnall A., Rochester L., Burn D.J. The interplay of cholinergic function, attention, and falls in Parkinson's disease. Mov. Disord. 2011, 26:2496-2503.
184. Yin H.H. Action, time and the basal ganglia. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2014, 369:20120473.
185. Yogev-Seligmann G., Giladi N., Gruendlinger L., Hausdorff J.M. The contribution of postural control and bilateral coordination to the impact of dual tasking on gait. Exp. Brain Res. 2013, 226:81-93.
186. Young W.R., Hollands M.A. Can telling older adults where to look reduce falls? Evidence for a causal link between inappropriate visual sampling and suboptimal stepping performance. Exp. Brain Res. 2010, 204:103-113.
187. Yue F., Zeng S., Wu D., Yi D., Alex Zhang Y., Chan P. Age-related decline in motor behavior and striatal dopamine transporter in cynomolgus monkeys. J. Neural Transm. 2012, 119:943-952.
188. Zaborszky L. The modular organization of brain systems. Basal forebrain: the last frontier. Prog. Brain Res. 2002, 136:359-372.
189. Zaborszky L., Buhl D.L., Pobalashingham S., Bjaalie J.G., Nadasdy Z. Three-dimensional chemoarchitecture of the basal forebrain: spatially specific association of cholinergic and calcium binding protein-containing neurons. Neuroscience 2005, 136:697-713.
190. Zaborszky L., Hoemke L., Mohlberg H., Schleicher A., Amunts K., Zilles K. Stereotaxic probabilistic maps of the magnocellular cell groups in human basal forebrain. Neuroimage 2008, 42:1127-1141.
191. Zaborszky L., van den Pol A., Gyengesi E. The basal forebrain cholinergic projection system in mice. The mouse nervous system 2012, 684-718. Elsevier.
192. Zaborszky L., Csordas A., Mosca K., Kim J., Gielow R., Vadasz C., et al. Neurons in the basal forebrain project to the cortex in a complex topographic organization that reflects corticocortical connectivity patterns: an experimental study based on retrograde tracing and 3D reconstruction. Cereb. Cortex 2013.
193. Ziegler D.A., Wonderlick J.S., Ashourian P., Hansen L.A., Young J.C., Murphy A.J., et al. Substantia nigra volume loss before basal forebrain degeneration in early Parkinson disease. JAMA Neurol. 2013, 70:241-247.